A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
8. März 2017 aktualisiert von: Hoffmann-La Roche
A Phase IV, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBe-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2a 40kD (Peg-IFN) ± Nucleos(t)Ide Analogue
This Phase 4 study is designed for the collection of blood biomarker samples from participants who have completed CHB treatment with at least 24 weeks of a pegylated interferon alfa-2a (Peg-IFN alfa-2a) containing regimen and at least 24 weeks post-treatment follow-up.
Participants may be enrolled from historical studies supported or sponsored by Roche, ongoing studies supported or sponsored by Roche, or from general medical practice.
The follow-up of individuals who choose to participate in this study will be in accordance with the ongoing studies or with the general medical practice of the physician.
Data from whole blood deoxyribonucleic acid (DNA) samples collected in the GV28555 study or available from previously collected Roche Clinical Repository (RCR) samples will be used for combined analysis with data from other applicable studies.
Procedures will include blood sample collection (not applicable for participants who previously have consented and donated RCR DNA samples) and medical record capture.
Studienübersicht
Status
Status
Abgeschlossen
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Beobachtungs
Einschreibung (Tatsächlich)
Einschreibung
1669
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Sofia, Bulgarien, 1407
- MHAT Tokuda Hospital Sofia; Department of Gastroenterology at Clinic of Internal Deseases
-
Varna, Bulgarien, 9010
- Mhat Sveta Marina; Clinic of Gastroenterology
-
-
-
-
-
Beijing, China, 100044
- Peking University People's Hospital
-
Beijing, China, 100011
- Beijing Ditan Hospital
-
Beijing, China, 100039
- Beijing 302 Hospital; No. 2 Infectious Disease Section
-
Beijing, China, 100069
- Beijing You An Hospital; Digestive Dept
-
Changsha, China, 410008
- Xiangya Hospital of Centre-South University
-
Chengdu, China, 610041
- West China Hospital, Sichuan University
-
Chongqing, China, 400010
- The Second Affiliated Hospital, Chongqing Medical University
-
Fu Zhou, China, 350005
- The First Affiliated Hospital of Fujian Medical University
-
Guangzhou, China
- Guangdong General Hospital
-
Guangzhou, China, 510515
- Nanfang Hospital, Southern Medical University
-
Guangzhou, China, 510060
- The Eighth People's Hospital of Guangzhou
-
Hangzhou, China
- Hangzhou Sixth People's Hospital
-
Harbin, China, 150001
- The 1st Affiliated Hospital of Harbin Medical University
-
Jinan, China, 250021
- JiNan Infectious Diseases Hospital
-
Nanjing, China, 210003
- Nanjing No.2 Hospital; Liver Disease Department
-
Nanning, China, 530021
- The First Affiliate Hospital of Guangxi Medical University
-
Shanghai, China, 201508
- Shanghai Public Health Clinical Center
-
Shanghai, China, 200021
- Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
-
Shen Zhen, China, 518020
- Shenzhen Donghu Hospital
-
Shi Jiazhuang, China, 050051
- The Third Hospital of Hebei Medical University
-
Urumqi, China, 830001
- Xinjiang Uygur Autonomous Region Hospital of Chinese Traditional Medicine
-
Wuhan, China, 430030
- Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
-
Xi'an, China, 710038
- The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
-
Yinchuan, China, 750004
- General Hospital of Ningxia Medical University
-
Zhengzhou, China, 450003
- Henan Provincial People's Hospital
-
-
-
-
-
Berlin, Deutschland, 13353
- Charité Uni.-medizin Berlin, Campus Virchow-Klinikum; Med. Klinik m.S. Hepatologie Gastroenterologie
-
Berlin, Deutschland, 10117
- Praxis Dr. med. Christine John
-
Berlin, Deutschland, 10969
- Praxis Dr. Heyne
-
Hamburg, Deutschland, 20099
- Ifi- Studien und Projekte GmbH, An der Asklepios Klinik St. Georg
-
Hannover, Deutschland, 30625
- Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie
-
-
-
-
-
Clichy, Frankreich, 92118
- Hopital Beaujon;Hepatologie
-
Creteil, Frankreich, 94010
- Hopital Henri Mondor; Hepatologie Gastro Enterologie
-
Rennes, Frankreich, 35033
- Hopital de Pontchaillou; Medicine Interne - Hepatologie
-
Saint Laurent Du Var, Frankreich, 06721
- Institut Arnault Tzanck; Medecine I Gastro Enterologie
-
-
-
-
-
Athens, Griechenland, 115 27
- Laiko General Hospital Athen; Uni Clinic of Gastrenterology
-
Larissa, Griechenland, 41 110
- University Hospital of Larissa; Pathological Clinic
-
Thessaloniki, Griechenland, 546 42
- Hippokratio Hospital; 4Th Internal Medicine Dpt
-
-
-
-
Campania
-
Caserta, Campania, Italien, 81100
- Az. Osp. S. Sebastiano; Divisione Malattie Infettive
-
Napoli, Campania, Italien, 80131
- Az. Osp. Cardarelli; Unita Operativa A Struttura Complessa Di Epatologia
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italien, 40138
- UNI DEGLI STUDI - POLICLINICA S. ORSOLA; Dipartimento Malattie dell'Apparato Digerente e Medicina In
-
Parma, Emilia-Romagna, Italien, 43100
- Az. Osp. Uni Ria Di Parma; Gastro-Enterology
-
-
Lombardia
-
Milano, Lombardia, Italien, 20122
- Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
-
Milano, Lombardia, Italien, 20122
- Ospedale Maggiore Policlinico; Iii Divisione Medicina Generale
-
-
Puglia
-
Bari, Puglia, Italien, 70124
- Azienda Ospedaliera Policlinico Consorziale di Bari; Clinica Malattie Infettive
-
Castellana Grotte, Puglia, Italien, 70013
- Ospedale de Bellis; Reparto Medicina Generale
-
-
Sardegna
-
Cagliari, Sardegna, Italien, 09042
- Uni Di Cagliari; Dept. Di Scienze Mediche
-
-
Sicilia
-
Palermo, Sicilia, Italien, 90127
- Istituto Di Clinica Medica 1 A; Divisione Di Medicina Generale E Gastroenterologia
-
-
Toscana
-
Pisa, Toscana, Italien, 56124
- Ospedale Cisanello - Az. Osp. Pisana; Unità Operativa Di Gastroenterologia Ed Epatologia
-
-
Veneto
-
Padova, Veneto, Italien, 35128
- Az. Osp. Di Padova; Dipart. Scienze Chirurgiche E Gastroent.
-
-
-
-
-
Busan, Korea, Republik von, 633-165
- Inje University Busan Paik Hospital; Nephrology
-
Chooncheon, Korea, Republik von, 200-060
- Chooncheon Sacred Heart Hospital
-
Seoul, Korea, Republik von, 135-710
- Samsung Medical Center; Gastroenterology
-
-
-
-
-
Auckland, Neuseeland, 100
- Auckland Hospital; New Zealand Liver Transplant Unit
-
-
-
-
-
Bydgoszcz, Polen, 85-030
- Hospital For Infectious Diseases; Infectiology
-
Chorzow, Polen, 41-500
- Szpital Specjalistyczny; Oddzial Obserwacyjno - Zakayny
-
Krakow, Polen, 31-202
- Krakowski Szpital Specjalistyczny im. Jana Pawla II; Oddzial Wirusowego Zapalenia Watroby
-
Lancut, Polen, 37-100
- Centrum Medyczne
-
Warszawa, Polen, 02-507
- Centralny Szpital Kliniczny MSWiA; Oddzial Chorob Wewnetrznych i Hepatologii
-
Warszawa, Polen, 01-201
- Wojewodzki Szpital Zakazny; Klinika Chorob Zakaznych
-
Zielona Góra, Polen, 65-044
- NZOZ Lubuska Specjalistyczna Poradnia Chorob Watroby
-
Łodz, Polen, 91-347
- Specjalistyczny Szpital Wojewódzki im. Biegańskiego; Klinika Chorób Zakaźnych i Hepatologii UM
-
-
-
-
-
Lisboa, Portugal, 1649-035
- Hospital de Santa Maria; Servico de Gastrenterologia e Hepatologia
-
Porto, Portugal, 4099-001
- Hospital Geral de Santo Antonio; Servico de Gastrenterologia
-
Porto, Portugal, 4202-451
- Hospital de Sao Joao; Servico de Gastrenterologia
-
-
-
-
-
Bucharest, Rumänien, 021105
- Institutul De Boli Infectioase Matei Bals; Sectia Clinica II Boli Infectioase Adulti
-
Bucharest, Rumänien, 030303
- The Hospital of Tropical and Infectious Disease Victor Babes
-
Craiova, Rumänien, 200515
- Clinical Infectious Diseases Hospital Victor Babes
-
-
-
-
-
Changhua, Taiwan, 500
- Changhua Christian Hospital; Internal Medicine
-
Kaohsiung, Taiwan, 807
- Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine
-
Kaohsiung, Taiwan, 00833
- Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine
-
Keelung City, Taiwan, 204
- Chang Gung Medical Foundation - Keelung; Dept. of Hepato-Gastroenterology
-
Taichung, Taiwan, 404
- China Medical University Hospital; Department of Rheumatology
-
Taipei, Taiwan, 112
- Taipei Veterans General Hospital; Gastroenterology Division
-
Taipei, Taiwan, 100
- National Taiwan Uni Hospital; Gastro-Enterology Dept.
-
Taipei, Taiwan
- Tri-Service Hospital; Dept. of Internal Medicine
-
Taoyuan, Taiwan, 333
- Chang Gung Medical Foundation - Linkou; Dept. of Hepato-Gastroenterology
-
-
-
-
-
Bangkok, Thailand, 10700
- Siriraj Hospital
-
Chiang Mai, Thailand, 50200
- Chiang Mai Uni Hospital; Faculty of Medicine
-
Songkhla, Thailand, 90112
- Songklanagarind Hospital; Division of Gastroenterology
-
-
-
-
-
London, Vereinigtes Königreich, E1 1BB
- The Royal London Hospital
-
Manchester, Vereinigtes Königreich, M13 9WL
- Manchester Royal Infirmary; Department Of Medicine
-
-
-
-
-
Wien, Österreich, 1090
- Medizinische Universität Wien; Univ.Klinik für Innere Medizin III - Gastroenterologie & Hepatologie
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Probenahmeverfahren
Wahrscheinlichkeitsstichprobe
Studienpopulation
Participants with CHB who received therapy with Peg-IFN ± nucleoside/nucleotide analogue will be included.
Beschreibung
Inclusion Criteria:
- Adults greater than or equal to (≥) 18 years of age
- CHB
- Previously enrolled in a Roche study and treated for CHB for ≥24 weeks with Peg-IFN ± nucleoside analogue (lamivudine or entecavir) or Peg-IFN ± nucleotide analogue (adefovir) and with ≥24 weeks post-treatment follow-up; or
- Treated in general practice for CHB with Peg-IFN according to standard of care and in line with the current Summary of Product Characteristics (SmPC)/local labeling who have no contraindication to Peg-IFN therapy as per local label and have been treated with Peg-IFN for ≥24 weeks and have ≥24 week post-treatment response available at the time of blood sample collection
Exclusion Criteria:
- Hepatitis A, hepatitis C, or human immunodeficiency virus (HIV) infection
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Anzahl der Gruppen / Kohorten
1
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Adult CHB Participants Treated With Peg-IFN Alfa-2a
Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included.
Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
|
Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks.
Dosing was chosen according to standard of care or at the discretion of the treating physician.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Single Nucleotide Polymorphisms (SNPs) Associated With HBeAg Seroconversion or Hepatitis B Surface Antigen (HBsAg) Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive East Asian (CN) Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Genome-wide association study (GWAS) approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of the antibody to HBeAg (anti-HBe).
HBsAg clearance was defined as the loss of HBsAg, with or without detection of the antibody to HBsAg (anti-HBs).
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as HBV DNA level below the lower limit of detection (LLD) of 2000 international units per milliliter (IU/mL).
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative Non-East Asian (Non-CN) Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs17037122) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative Non-CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs17037122) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs2464266) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in Non-CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in Non-CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs17037122) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in Non-CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in Non-CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined criterion in treatment response.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBsAg Clearance ≥24 Weeks Post-Treatment in Non-CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs12992677) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBsAg Clearance ≥24 Weeks Post-Treatment in Non-CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs12992677) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBsAg Clearance ≥24 Weeks Post-Treatment in CN Population: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs7549785) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBsAg Clearance ≥24 Weeks Post-Treatment in CN Population: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs7549785) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBsAg Clearance ≥24 Weeks Post-Treatment: Additive Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to additive models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
|
Single blood sample ≥24 weeks post-treatment
|
|
SNPs Associated With HBsAg Clearance ≥24 Weeks Post-Treatment: Dominant Model
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
GWAS approach was used to evaluate the association of SNPs with treatment response.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Associations with treatment response were analyzed using logistic regression and adjusted for covariates.
Markers were coded according to dominant models of inheritance.
Markers surpassing p-value thresholds of p<10^-5 and p<5x10^-8 were considered suggestive and genome-wide significant, respectively.
Larger beta coefficients correspond to greater likelihood of treatment response.
Only a single SNP (rs6592052) was included in the analysis.
|
Single blood sample ≥24 weeks post-treatment
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants With HBeAg Seroconversion or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Non-CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion Plus Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined endpoint in this outcome measure.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion Plus Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined endpoint in this outcome measure.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion Plus Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Positive Non-CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined endpoint in this outcome measure.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With Undetectable HBV DNA or HBsAg Clearance ≥24 Weeks Post-Treatment in HBeAg-Negative Non-CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in Non-CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined endpoint in this outcome measure.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined endpoint in this outcome measure.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBeAg Seroconversion Plus Undetectable HBV DNA, HBsAg Clearance, or Undetectable HBV DNA ≥24 Weeks Post-Treatment in Non-CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBeAg seroconversion was defined as the loss of HBeAg and detection of anti-HBe.
Undetectable HBV DNA was defined as an HBV DNA level below the LLD of 2000 IU/mL.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
HBeAg seroconversion and undetectable HBV DNA were a combined endpoint in this outcome measure.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBsAg Clearance ≥24 Weeks Post-Treatment
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBsAg Clearance ≥24 Weeks Post-Treatment in CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
|
Number of Participants With HBsAg Clearance ≥24 Weeks Post-Treatment in Non-CN Population
Zeitfenster: Single blood sample ≥24 weeks post-treatment
|
Single blood samples were used to analyze HBV serology and genotype data at least 24 weeks post-treatment.
HBsAg clearance was defined as the loss of HBsAg, with or without detection of anti-HBs.
|
Single blood sample ≥24 weeks post-treatment
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
20. August 2013
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
28. November 2014
Studienabschluss (Tatsächlich)
Studienabschluss
28. November 2014
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
8. Mai 2013
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
14. Mai 2013
Zuerst gepostet (Schätzen)
Zuerst gepostet
17. Mai 2013
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
5. April 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
8. März 2017
Zuletzt verifiziert
Zuletzt verifiziert
1. März 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Hepadnaviridae-Infektionen
- DNA-Virusinfektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, chronisch
- Antiinfektiva
- Antivirale Mittel
- Antineoplastische Mittel
- Peginterferon alfa-2a
- Interferon alpha-2
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- GV28855
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .